N-terminal propeptide of type 1 procollagen
EstablishedP1NP is the leading bone formation marker, used to monitor both anabolic and antiresorptive osteoporosis therapy.
P1NP measures how fast new bone is being built. Doctors watch it after starting bone-building osteoporosis drugs to make sure it's rising as expected, which is the opposite of what should happen with the more common bone-thinning-slowing drugs.
P1NP is a byproduct released when new type I collagen is formed during bone building, serving as the leading marker of bone formation activity, complementary to resorption markers like CTX.
P1NP levels reflect the rate of new bone formation; it is used to monitor osteoporosis treatment response, with a distinctive expected pattern depending on drug class — P1NP should rise with anabolic (bone-building) drugs like teriparatide, but fall with antiresorptive drugs like bisphosphonates.
Measured via serum immunoassay, typically alongside CTX (a resorption marker) for a complete bone-turnover picture; a substantial rise in P1NP after starting an anabolic osteoporosis drug confirms the expected pharmacologic effect.
P1NP is used to confirm adequate response to anabolic osteoporosis therapy and, alongside CTX, to monitor antiresorptive treatment adherence and effectiveness over the first 3-6 months of therapy.
Expected direction of change differs by drug class — rising with anabolic drugs, falling with antiresorptive drugs.
- Cleveland Clinic Journal of Medicine. (2023). Making best use of bone turnover markers to monitor oral bisphosphonate therapy.